The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes

PPAR Research

Volumn , Issue , 2012, Pages

  Thomas, M C ^a   Jandeleit Dahm, K A ^a   Tikellis, C ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; ROSIGLITAZONE;

BLOOD PRESSURE; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULOSCLEROSIS; HUMAN; HYPOXIA; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY HYPERTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PODOCYTE; PROTEIN EXPRESSION; RENAL PROTECTION; REVIEW;

EID: 84863418988     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/456529     Document Type: Review

References (115)

1. Barish G. D., Narkar V. A., Evans R. M., PPAR : a dagger in the heart of the metabolic syndrome Journal of Clinical Investigation 2006 116 3 590 597 (Pubitemid 43326863)
2. Groop P. H., Thomas M. C., Moran J. L., Wadn J., Thorn L. M., Mkinen V. P., Rosengrd-Brlund M., Saraheimo M., Hietala K., Heikkil O., Forsblom C., The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes Diabetes 2009 58 7 1651 1658
3. Stephenson J. M., Kenny S., Stevens L. K., Fuller J. H., Lee E., Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes Diabetic Medicine 1995 12 2 149 155
4. Adler A. I., Stevens R. J., Manley S. E., Bilous R. W., Cull C. A., Holman R. R., Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney International 2003 63 1 225 232 (Pubitemid 35463925)
5. Spiegelman B. M., PPAR- : adipogenic regulator and thiazolidinedione receptor Diabetes 1998 47 4 507 514 (Pubitemid 28160438)
6. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation Nature 1998 391 6662 79 82 (Pubitemid 28079218)
7. Camp H. S., Li O., Wise S. C., Hong Y. H., Frankowski C. L., Shen X. Q., Vanbogelen R., Leff T., Differential activation of peroxisome proliferator-activated receptor- by troglitazone and rosiglitazone Diabetes 2000 49 4 539 547 (Pubitemid 30183741)
8. Kamijo Y., Hora K., Tanaka N., Usuda N., Kiyosawa K., Nakajima T., Gonzalez F. J., Aoyama T., Identification of functions of peroxisome proliferator-activated receptor in proximal tubules Journal of the American Society of Nephrology 2002 13 7 1691 1702 (Pubitemid 34700593)
9. Ouali F., Djouadi F., Merlet-Bénichou C., Bastin J., Dietary lipids regulate -oxidation enzyme gene expression in the developing rat kidney American Journal of Physiology 1998 275 5 F777 F784
10. Johnson E. F., Palmer C. N. A., Griffin K. J., Hsu M. H., Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation The FASEB Journal 1996 10 11 1241 1248 (Pubitemid 26307509)
11. Mukherjee R., Jow L., Croston G. E., Paterniti J. R., Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR 2 versus PPAR 1 and activation with retinoid X receptor agonists and antagonists Journal of Biological Chemistry 1997 272 12 8071 8076 (Pubitemid 27137374)
12. Guan Y., Zhang Y., Davis L., Breyer M. D., Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans American Journal of Physiology 1997 273 6 F1013 F1022
13. Kliewer S. A., Forman B. M., Blumberg B., Ong E. S., Borgmeyer U., Mangelsdorf D. J., Umesono K., Evans R. M., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359 (Pubitemid 24226862)
14. Inamoto T., Shah J. B., Kamat A. M., Friend or foe? Role of peroxisome proliferator-activated receptor- in human bladder cancer Urologic Oncology 2009 27 6 585 591
15. Sato K., Sugawara A., Kudo M., Uruno A., Ito S., Takeuchi K., Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney Hypertension Research 2004 27 6 417 425 (Pubitemid 38996932)
16. Yang T., Michele D. E., Park J., Smart A. M., Lin Z., Brosius F. C., Schnermann J. B., Briggs J. P., Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney American Journal of Physiology 1999 277 6 F966 F973
17. Zhou Y. T., Shimabukuro M., Wang M. Y., Lee Y., Higa M., Milburn J. L., Newgard C. B., Unger R. H., Role of peroxisome proliferator-activated receptor in disease of pancreatic cells Proceedings of the National Academy of Sciences of the United States of America 1998 95 15 8898 8903 (Pubitemid 28350586)
18. Joly E., Roduit R., Peyot M. L., Habinowski S. A., Ruderman N. B., Witters L. A., Prentki M., Glucose represses PPAR gene expression via AMP-activated protein kinase but not via p38 mitogen-activated protein kinase in the pancreatic -cell Journal of Diabetes 2009 1 4 263 272
19. Mishra R., Emancipator S. N., Miller C., Kern T., Simonson M. S., Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney American Journal of Physiology 2004 286 5 F913 F921
20. Park C. W., Kim H. W., Ko S. H., Hyun W. C., Sun W. L., Chul W. Y., Yoon S. C., Sugawara A., Guan Y., Breyer M. D., Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor Diabetes 2006 55 4 885 893 (Pubitemid 44100160)
21. Panchapakesan U., Pollock C. A., Chen X. M., The effect of high glucose and PPAR- agonists on PPAR- expression and function in HK-2 cells American Journal of Physiology 2004 287 3 F528 F534
22. Zheng F., Fornoni A., Elliot S. J., Guan Y., Breyer M. D., Striker L. J., Striker G. E., Upregulation of type I collagen by TGF- in mesangial cells is blocked by PPAR activation American Journal of Physiology 2002 282 4 F639 F648
23. Rodrguez-Calvo R., Serrano L., Coll T., Moullan N., Snchez R. M., Merlos M., Palomer X., Laguna J. C., Michalik L., Wahli W., Vzquez-Carrera M., Activation of peroxisome proliferator-activated receptor / inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor- B activity via extracellular signal-related kinase 1/2 Diabetes 2008 57 8 2149 2157
24. Lepenies J., Hewison M., Stewart P. M., Quinkler M., Renal PPAR mRNA expression increases with impairment of renal function in patients with chronic kidney disease Nephrology 2010 15 7 683 691
25. Calkin A. C., Giunti S., Jandeleit-Dahm K. A., Allen T. J., Cooper M. E., Thomas M. C., PPAR- and agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse Nephrology Dialysis Transplantation 2006 21 9 2399 2405 (Pubitemid 44644510)
26. Park C. W., Zhang Y., Zhang X., Wu J., Chen L., Cha D. R., Su D., Hwang M. T., Fan X., Davis L., Striker G., Zheng F., Breyer M., Guan Y., PPAR agonist fenofibrate improves diabetic nephropathy in db/db mic Kidney International 2006 69 9 1511 1517
27. Ren S., Xin C., Beck K. F., Saleem M. A., Mathieson P., Pavenstdt H., Pfeilschifter J., Huwiler A., PPAR activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism Biochemical and Biophysical Research Communications 2005 338 4 1818 1824 (Pubitemid 41643096)
28. Zhao X., Li L. Y., PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats American Journal of Nephrology 2008 28 4 598 606 (Pubitemid 351832447)
29. Isshiki K., Haneda M., Koya D., Maeda S., Sugimoto T., Kikkawa R., Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats Diabetes 2000 49 6 1022 1032 (Pubitemid 30349426)
30. Fujii M., Takemura R., Yamaguchi M., Hasegawa G., Shigeta H., Nakano K., Kondo M., Troglitazone (CS-045) ameliorates albuminuria in streptozotocin- induced diabetic rats Metabolism 1997 46 9 981 983 (Pubitemid 27371810)
31. Buckingham R. E., Al-Barazanji K. A., Toseland C. D. N., Slaughter M., Connor S. C., West A., Bond B., Turner N. C., Clapham J. C., Peroxisome proliferator-activated receptor- agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in zucker fatty rats Diabetes 1998 47 8 1326 1334 (Pubitemid 28357012)
32. Calkin A. C., Forbes J. M., Smith C. M., Lassila M., Cooper M. E., Jandeleit-Dahm K. A., Allen T. J., Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 9 1903 1909 (Pubitemid 41243461)
33. Calkin A. C., Cooper M. E., Jandeleit-Dahm K. A., Allen T. J., Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation Diabetologia 2006 49 4 766 774 (Pubitemid 43357552)
34. Ansquer J. C., Foucher C., Rattier S., Taskinen M. R., Steiner G., Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) American Journal of Kidney Diseases 2005 45 3 485 493 (Pubitemid 40341327)
35. Keech A., Simes R. J., Barter P., Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial The Lancet 2005 366 9500 1849 1861
36. Ginsberg H. N., Elam M. B., Lovato L. C., Crouse J. R., Leiter L. A., Linz P., Friedewald W. T., Buse J. B., Gerstein H. C., Probstfield J., Grimm R. H., Ismail-Beigi F., Bigger J. T., Goff D. C., Cushman W. C., Simons-Morton D. G., Byington R. P., Effects of combination lipid therapy in type 2 diabetes mellitus The New England Journal of Medicine 2010 362 17 1563 1574
37. Smolders Y. M., Van Eeden A. E., Stehouwer C. D. A., Weijers R. N. M., Slaats E. H., Silberbusch J., Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? European Journal of Clinical Investigation 1997 27 12 997 1002 (Pubitemid 28012621)
38. Thomas M. C., Rosengrd-Brlund M., Mills V., Rnnback M., Thomas S., Forsblom C., Cooper M. E., Taskinen M. R., Viberti G., Groop P. H., Serum lipids and the progression of nephropathy in type 1 diabetes Diabetes Care 2006 29 2 317 322 (Pubitemid 44106511)
39. Tolonen N., Forsblom C., Thorn L., Wadén J., Rosengrd-Brlund M., Saraheimo M., Feodoroff M., Mkinen V. P., Gordin D., Taskinen M. R., Groop P. H., Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes Diabetologia 2009 52 12 2522 2530
40. Colhoun H. M., Bennett P. H., Lu M., Risk factors for renal failure: the WHO multinational study of vascular disease in diabetes Diabetologia 2001 44 supplement 2 S46 S53
41. Ruan X. Z., Varghese Z., Moorhead J. F., An update on the lipid nephrotoxicity hypothesis Nature Reviews Nephrology 2009 5 12 713 721
42. Vergs B., Diabetic dyslipidaemia: insights for optimizing patient management Current Medical Research and Opinion 2005 21 supplement 1 S29 S40
43. Taskinen M. R., Diabetic dyslipidaemia: from basic research to clinical practice Diabetologia 2003 46 6 733 749
44. Duvillard L., Florentin E., Lizard G., Petit J. M., Galland F., Monier S., Gambert P., Vergs B., Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy Diabetes Care 2003 26 5 1540 1544 (Pubitemid 36929193)
45. Cockerill G. W., Huehns T. Y., Weerasinghe A., Stocker C., Lerch P. G., Miller N. E., Haskard D. O., Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation Circulation 2001 103 1 108 112 (Pubitemid 32050444)
46. Ashby D. T., Rye K. A., Clay M. A., Vadas M. A., Gamble J. R., Barter P. J., Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 9 1450 1455 (Pubitemid 28421883)
47. Hulthe J., Fagerberg B., Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study) Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 7 1162 1167 (Pubitemid 34764868)
48. Shin S. J., Lim J. H., Chung S., Youn D. Y., Chung H. W., Kim H. W., Lee J. W., Chang Y. S., Park C. W., Peroxisome proliferator-activated receptor- activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats Hypertension Research 2009 32 10 835 845
49. Gonzalez F. J., Recent update on the PPAR -null mouse Biochimie 1997 79 2-3 139 144 (Pubitemid 27290357)
50. Hattori Y., Hattori S., Kasai K., Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells Hypertension 1999 33 4 943 948 (Pubitemid 29186389)
51. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R. M., PPAR- dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nature Medicine 2001 7 1 48 52 (Pubitemid 32095641)
52. Calkin A. C., Cooper M. E., Jandeleit-Dahm K. A., Allen T. J., Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation Diabetologia 2006 49 4 766 774 (Pubitemid 43357552)
53. Asaba K., Tojo A., Onozato M. L., Goto A., Quinn M. T., Fujita T., Wilcox C. S., Effects of NADPH oxidase inhibitor in diabetic nephropathy Kidney International 2005 67 5 1890 1898 (Pubitemid 40577724)
54. Wilmer W. A., Dixon C. L., Hebert C., Lu L., Rovin B. H., PPAR- ligands inhibit H2O2-mediated activation of transforming growth factor- 1 in human mesangial cells Antioxidants and Redox Signaling 2002 4 6 877 884 (Pubitemid 36042463)
55. Evans M., Anderson R. A., Graham J., Ellis G. R., Morris K., Davies S., Jackson S. K., Lewis M. J., Frenneaux M. P., Rees A., Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus Circulation 2000 101 15 1773 1779 (Pubitemid 30213097)
56. Brownlee M., Biochemistry and molecular cell biology of diabetic complications Nature 2001 414 6865 813 820 (Pubitemid 34000785)
57. Forbes J. M., Coughlan M. T., Cooper M. E., Oxidative stress as a major culprit in kidney disease in diabetes Diabetes 2008 57 6 1446 1454
58. Chacko B. K., Reily C., Srivastava A., Johnson M. S., Ye Y., Ulasova E., Agarwal A., Zinn K. R., Murphy M. P., Kalyanaraman B., Darley-Usmar V., Prevention of diabetic nephropathy in Ins2 Biochemical Journal 2010 432 1 9 19
59. Yao C. X., Li W. Y., Zhang S. F., Zhang S. F., Zhang H. F., Zang M. X., Effects of doxorubicin and fenofibrate on the activities of NADH oxidase and citrate synthase in mice Basic and Clinical Pharmacology and Toxicology 2011 109 6 452 456
60. Krysiak R., Gdula-Dymek A., Okopien B., Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia American Journal of Cardiology 2011 107 7 1010 e1
61. Tonelli J., Li W., Kishore P., Pajvani U. B., Kwon E., Weaver C., Scherer P. E., Hawkins M., Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes Diabetes 2004 53 6 1621 1629 (Pubitemid 38697679)
62. Li L., Emmett N., Mann D., Zhao X., Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor- B and transforming growth factor- 1/Smad3 in diabetic nephropathy Experimental Biology and Medicine 2010 235 3 383 391
63. Marx N., Sukhova G. K., Collins T., Libby P., Plutzky J., PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 1999 99 24 3125 3131 (Pubitemid 29289077)
64. Marx N., Mackman N., Schnbeck U., Yilmaz N., Hombach V., Libby P., Plutzky J., PPAR activators inhibit tissue factor expression and activity in human monocytes Circulation 2001 103 2 213 219 (Pubitemid 32095405)
65. Neve B. P., Corseaux D., Chinetti G., Zawadzki C., Fruchart J. C., Duriez P., Staels B., Jude B., PPAR agonists inhibit tissue factor expression in human monocytes and macrophages Circulation 2001 103 2 207 212 (Pubitemid 32095404)
66. Ziyadeh F. N., Wolf G., Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy Current Diabetes Reviews 2008 4 1 39 45 (Pubitemid 351210971)
67. Wolf G., Chen S., Ziyadeh F. N., From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy Diabetes 2005 54 6 1626 1634 (Pubitemid 40770751)
68. Li J. J., Kwak S. J., Jung D. S., Kim J. J., Yoo T. H., Ryu D. R., Han S. H., Choi H. Y., Lee J. E., Moon S. J., Kim D. K., Han D. S., Kang S. W., Podocyte biology in diabetic nephropathy Kidney International 2007 72 106 S36 S42
69. Seiler M. W., Rennke H. G., Venkatachalam M. A., Cotran R. S., Pathogenesis of polycation induced alterations ('fusion') of glomerular epithelium Laboratory Investigation 1977 36 1 48 61 (Pubitemid 8021270)
70. Welsh G. I., Hale L. J., Eremina V., Jeansson M., Maezawa Y., Lennon R., Pons D. A., Owen R. J., Satchell S. C., Miles M. J., Caunt C. J., McArdle C. A., Pavenstdt H., Tavaré J. M., Herzenberg A. M., Kahn C. R., Mathieson P. W., Quaggin S. E., Saleem M. A., Coward R. J. M., Insulin signaling to the glomerular podocyte is critical for normal kidney function Cell Metabolism 2010 12 4 329 340
71. Zhu C., Huang S., Yuan Y., Ding G., Chen R., Liu B., Yang T., Zhang A., Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPAR American Journal of Pathology 2011 178 5 2020 2031
72. Lennon R., Welsh G. I., Singh A., Satchell S. C., Coward R. J., Tavaré J. M., Mathieson P. W., Saleem M. A., Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1 Diabetologia 2009 52 9 1944 1952
73. Yang H. C., Ma L. J., Ma J., Fogo A. B., Peroxisome proliferator- activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis Kidney International 2006 69 10 1756 1764 (Pubitemid 43739202)
74. Benigni A., Zoja C., Tomasoni S., Campana M., Corna D., Zanchi C., Gagliardini E., Garofano E., Rottoli D., Ito T., Remuzzi G., Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor- agonist: molecular mechanism of the antiproteinuric effect of pioglitazone Journal of the American Society of Nephrology 2006 17 6 1624 1632 (Pubitemid 43794665)
75. Davis T. M. E., Ting R., Best J. D., Donoghoe M. W., Drury P. L., Sullivan D. R., Jenkins A. J., O'Connell R. L., Whiting M. J., Glasziou P. P., Simes R. J., Kesniemi Y. A., Gebski V. J., Scott R. S., Keech A. C., Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 2011 54 2 280 290
76. Wang H., Deng J. L., Yue J., Li J., Hou Y. B., Prostaglandin E1 for preventing the progression of diabetic kidney disease Cochrane Database of Systematic Reviews 2010 5, article CD006872
77. Ma L. J., Marcantoni C., Linton M. F., Fazio S., Fogo A. B., Peroxisome proliferator-activated receptor- agonist troglitazone protects against nondiabetic glomerulosclerosis in rats Kidney International 2001 59 5 1899 1910 (Pubitemid 32336806)
78. Yang H. C., Deleuze S., Zuo Y., Potthoff S. A., Ma L. J., Fogo A. B., The PPAR agonist pioglitazone ameliorates aging-related progressive renal injury Journal of the American Society of Nephrology 2009 20 11 2380 2388
79. Sarafidis P. A., Stafylas P. C., Georgianos P. I., Saratzis A. N., Lasaridis A. N., Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis American Journal of Kidney Diseases 2010 55 5 835 847
80. Schneider C. A., Ferrannini E., DeFronzo R., Schernthaner G., Yates J., Erdmann E., Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease Journal of the American Society of Nephrology 2008 19 1 182 187
81. Herrmann S. M., Ringel J., Wang J. G., Staessen J. A., Brand E., Peroxisome proliferator-activated receptor- 2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study Diabetes 2002 51 8 2653 2657 (Pubitemid 34827420)
82. De Cosmo S., Prudente S., Lamacchia O., Lapice E., Morini E., Di Paola R., Copetti M., Ruggenenti P., Remuzzi G., Vaccaro O., Cignarelli M., Trischitta V., PPAR 2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies Nephrology Dialysis Transplantation 2011 26 12 4011 4016
83. Jorsal A., Tarnow L., Lajer M., Ek J., Hansen T., Pedersen O., Parving H. H., The PPAR 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy Molecular Genetics and Metabolism 2008 94 3 347 351
84. Bell D. S. H., -Cell rejuvenation with thiazolidinediones American Journal of Medicine 2003 115 8 20 23
85. Groop P. H., Forsblom C., Thomas M. C., Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes Nature Clinical Practice 2005 1 2 100 110
86. Ohtomo S., Izuhara Y., Takizawa S., Yamada N., Kakuta T., Van Ypersele De Strihou C., Miyata T., Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model Kidney International 2007 72 12 1512 1519 (Pubitemid 350197953)
87. Chinetti G., Lestavel S., Bocher V., Remaley A. T., Neve B., Torra I. P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H. B., Fruchart J. C., Clavey V., Staels B., PPAR- and PPAR- activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nature Medicine 2001 7 1 53 58 (Pubitemid 32095642)
88. Efrati S., Berman S., Ilgiyeav E., Averbukh Z., Weissgarten J., PPAR- activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats Nephron Experimental Nephrology 2007 106 4 e107 e112
89. Goya K., Sumitani S., Otsuki M., Xu X., Yamamoto H., Kurebayashi S., Saito H., Kouhara H., Kasayama S., The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells Journal of Diabetes and its Complications 2006 20 5 336 342 (Pubitemid 44292533)
90. Rszer T., Ricote M., PPARs in the renal regulation of systemic blood pressure PPAR Research 2010 2010
91. Sugawara A., Uruno A., Kudo M., Matsuda K., Yang C. W., Ito S., Effects of PPAR on hypertension, atherosclerosis, and chronic kidney disease Endocrine Journal 2010 57 10 847 852
92. Meirhaeghe A., Amouyel P., Impact of genetic variation of PPAR in humans Molecular Genetics and Metabolism 2004 83 1-2 93 102 (Pubitemid 39311284)
93. Horiki M., Ikegami H., Fujisawa T., Kawabata Y., Ono M., Nishino M., Shimamoto K., Ogihara T., Association of Pro12Ala polymorphism of PPAR gene with insulin resistance and related diseases Diabetes Research and Clinical Practice 2004 66 supplement 1 S63 S67
94. Calkin A. C., Forbes J. M., Smith C. M., Lassila M., Cooper M. E., Jandeleit-Dahm K. A., Allen T. J., Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 9 1903 1909 (Pubitemid 41243461)
95. Gumieniczek A., Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals Experimental and Toxicologic Pathology 2005 56 4-5 321 326 (Pubitemid 40312757)
96. Gumieniczek A., Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits Life Sciences 2003 74 5 553 562 (Pubitemid 37419966)
97. Wilson-Fritch L., Burkart A., Bell G., Mendelson K., Leszyk J., Nicoloro S., Czech M., Corvera S., Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone Molecular and Cellular Biology 2003 23 3 1085 1094 (Pubitemid 36133524)
98. Matsui T., Yamagishi S. I., Takeuchi M., Ueda S., Fukami K., Okuda S., Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation Biochemical and Biophysical Research Communications 2010 398 2 326 330
99. Lai K. N., Chan L. Y. Y., Guo H., Tang S. C. W., Leung J. C. K., Additive effect of PPAR- agonist and ARB in treatment of experimental IgA nephropathy Pediatric Nephrology 2011 26 2 257 266
100. Okada T., Wada J., Hida K., Eguchi J., Hashimoto I., Baba M., Yasuhara A., Shikata K., Makino H., Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms Diabetes 2006 55 6 1666 1677 (Pubitemid 44324119)
101. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H., Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF- B activation American Journal of Physiology 2007 292 4 F1141 F1150
102. Whiteside C., Wang H., Xia L., Munk S., Goldberg H. J., Fantus I. G., Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells Experimental Diabetes Research 2009 2009 910783
103. Sharma K., RamachandraRao S., Qiu G., Usui H. K., Zhu Y., Dunn S. R., Ouedraogo R., Hough K., McCue P., Chan L., Falkner B., Goldstein B. J., Adiponectin regulates albuminuria and podocyte function in mice Journal of Clinical Investigation 2008 118 5 1645 1656 (Pubitemid 351632369)
104. Miyazaki Y., Cersosimo E., Triplitt C., DeFronzo R. A., Rosiglitazone decreases albuminuria in type 2 diabetic patients Kidney International 2007 72 11 1367 1373 (Pubitemid 350126770)
105. Guan Y., Hao C., Cha D. R., Rao R., Lu W., Kohan D. E., Magnuson M. A., Redha R., Zhang Y., Breyer M. D., Thiazolidinediones expand body fluid volume through PPAR stimulation of ENaC-mediated renal salt absorption Nature Medicine 2005 11 8 861 866 (Pubitemid 41161118)
106. Panchapakesan U., Pollock C., Saad S., Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake Nephrology 2009 14 3 298 301
107. Matsushita Y., Ogawa D., Wada J., Yamamoto N., Shikata K., Sato C., Tachibana H., Toyota N., Makino H., Activation of peroxisome proliferator-activated receptor inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice Diabetes 2011 60 3 960 968
108. Liang Y. J., Chen S. A., Jian J. H., Peroxisome proliferator-activated receptor downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice European Journal of Pharmaceutical Sciences 2011 43 1-2 65 70
109. Burch L. R., Donnelly L. A., Doney A. S. F., Brady J., Tommasi A. M., Whitley A. L., Goddard C., Morris A. D., Hansen M. K., Palmer C. N. A., Peroxisome proliferator-activated receptor- genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research tayside study Journal of Clinical Endocrinology and Metabolism 2010 95 4 1830 1837
110. Ooi E. M., Watts G. F., Sprecher D. L., Chan D. C., Barrett P. H., Mechanism of action of a Peroxisome Proliferator-Activated Receptor (PPAR)- agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity Journal of Clinical Endocrinology and Metabolism 2011 96 10 E1568 E1576
111. Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J. P., Heudes D., Wahli W., Desvergne B., Baud L., Peroxisome proliferator- activated receptor / exerts a strong protection from ischemic acute renal failure Journal of the American Society of Nephrology 2005 16 8 2395 2402 (Pubitemid 41725057)
112. Miyata T., Van Ypersele De Strihou C., Diabetic nephropathy: a disorder of oxygen metabolism? Nature Reviews Nephrology 2010 6 2 83 95
113. Yang X., Kume S., Tanaka Y., Isshiki K., Araki S. I., Chin-Kanasaki M., Sugimoto T., Koya D., Haneda M., Sugaya T., Li D., Han P., Nishio Y., Kashiwagi A., Maegawa H., Uzu T., GW501516, a PPAR agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NF B pathway in mice PLoS ONE 2011 6 9, article e25271
114. Lee C. H., Chawla A., Urbiztondo N., Liao D., Boisvert W. A., Evans R. M., Transcriptional repression of atherogenic inflammation: modulation by PPAR Science 2003 302 5644 453 457 (Pubitemid 37296272)
115. Liang Y. J., Jian J. H., Liu Y. C., Juang S. J., Shyu K. G., Lai L. P., Wang B. W., Leu J. G., Advanced glycation end products-induced apoptosis attenuated by PPAR activation and epigallocatechin gallate through NF- B pathway in human embryonic kidney cells and human mesangial cells Diabetes/Metabolism Research and Reviews 2010 26 5 406 416